NCT01809223

A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV

The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 176 (estimated)
• Sponsor: Chengdu Kanghong Biotech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.

Conditions

• Choroid Neovascularization Secondary to Degenerative Myopia

Interventions

Type	Name	Description
DRUG	conbercept, Fixed	intravitreal injection of 0.5 mg conbercept per month, fixed injection
DRUG	conbercept, PRN	intravitreal injection of 0.5 mg conbercept as need, PRN
OTHER	sham injection	sham intravitreal injection per month, fixed injection

Timeline

• Start date: 2012-08-01
• Primary completion: 2014-02-01
• Completion: 2015-03-01
• First posted: 2013-03-12
• Last updated: 2014-06-04

Locations

13 sites across 1 country: China